Platelet Rich Plasma: “The Process Is The Product”
Platelet-rich plasma or PRP, derived from the patient’s own blood, is considered by many to be an all-natural, safe product with rejuvenation properties. Here, we discuss what exactly is PRP, the qualities that would make an ideal PRP extraction system, and the work that lies ahead to standardize current treatment protocols.
Dr. Terrence Keaney led a lecture on platelet-rich plasma (PRP) at t …
Platelet-rich plasma or PRP, derived from the patient’s own blood, is considered by many to be an all-natural, safe product with rejuvenation properties. Here, we discuss what exactly is PRP, the qualities that would make an ideal PRP extraction system, and the work that lies ahead to standardize current treatment protocols.
Dr. Terrence Keaney led a lecture on platelet-rich plasma (PRP) at t … Continue reading "Platelet Rich Plasma: “The Process Is The Product”"
Who’s afraid of the Big Bad Wolves in pediatric dermatology? Whether in clinic or in the wards, we all have some bad wolves we hope not to encounter, and others that do not fail to surprise dermatologists. Here, I share a few of them as presented by Dr. Yasmine Kirkorian at the 2020 ODAC Dermatology, Aesthetic and Surgical Conference, including Mycoplasma-induced Rash and Mucositis (MIRM), Sta … 
Here are the June JDD Issue Highlights:
Guest Editor Dr. James Q. Del Rosso stresses that even the best case scenario of teledermatology can never offer the same as a live in-person visit in Virtual Exams No Substitute for In-Person Care of Acne and Rosacea.
Treating Inflammation in Rosacea: Current Options and Unmet Needs, authors discuss the underlying inflammatory nature of rosacea, tre … 
The patient developed this cutaneous adverse event 2 weeks after starting a clinical trial medication. What is the mechanism of action of the culprit medication?
A. Epidermal growth factor receptor (EGFR) inhibitor
B. Tumor necrosis factor (TNF)-alpha inhibitor
C. Smoothened inhibitor
D. BRAF inhibitor
E. Programmed cell death (PD)-1 inhibitor
To find out the correct answer and … 
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic and Surgical Conference, interviewed Dr. Jonathan Zippin, Vice-Chair of Research and an Associate Attending Dermatologist and Associate Professor of Dermatology at Weill Medical College of Cornell, and Director of the Contact, Occupational and Photodermatitis Service. Watch as he reviews the JAK/STAT signaling pathway in normal i …